I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Breast Neoplasms · Breast Cancer · Breast Tumors · Angiosarcoma · TNBC - Triple-Negative Breast Cancer · HER2-positive Breast Cancer · HER2-negative Breast Cancer · Hormone Receptor Positive Tumor · Hormone Receptor Negative Tumor · Early-stage Breast Cancer · Locally Advanced Breast Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • University of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Principal Investigator (Erica Stringer-Reasor, MD)
  • Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States

    Study coordinator · 507-538-7623
    Contact: Principal Investigator (Donald Northfelt, MD)
  • University of Arizona, Tucson, Arizona, United States

  • University of California - Davis, Comprehensive Cancer Center, Davis, California, United States

    Contact: Principal Investigator (Mili Arora, MD)
  • City of Hope, Duarte, California, United States

    Study coordinator · 800-826-4673
    Contact: Principal Investigator (Hope Rugo, MD)
  • University of California San Diego, La Jolla, California, United States

    Study coordinator · 858-822-6194
    Study coordinator · CancerCTO@ucsd.edu · 858-822-6194
    Contact: Principal Investigator (Anne Wallace, MD)
  • University of Southern California, Los Angeles, California, United States

    Contact: Study coordinator (Kristy Watkins, RN) · Watkins_K@ccnt.usc.edu · 323-865-0452
    Contact: Principal Investigator (Evanthia Roussos Torres, MD)
  • HOAG Memorial Hospital Presbyterian, Newport Beach, California, United States

    Contact: Principal Investigator (Chaitali Nangia, MD)
  • University of California San Francisco (UCSF), San Francisco, California, United States

    Contact: Study coordinator (Clinical Research Coordinator) · ispycrc@ucsf.edu · 415-443-4296
    Contact: Principal Investigator (Amy Jo Chien, MD)
  • University of Colorado Cancer Center, Aurora, Colorado, United States

    Study coordinator · 720-848-1622
    Anthony Elias, MD (Sub-investigator)
    Contact: Principal Investigator (Virgnia Borges, MD)
  • Yale Cancer Center, New Haven, Connecticut, United States

    Contact: Study coordinator (Trisha Burello, MS) · trisha.burrello@yale.edu · 203-737-2848
    Tara Snaft, MD (Sub-investigator)
    Lajos Pusztai, MD (Sub-investigator)
    Contact: Principal Investigator (Mariya Rozenblit, MD)
  • Georgetown University Medical Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Minetta Liu, MD) · Liumc@georgetown.edu · 202-444-3677
    Contact: Principal Investigator (Claudine Isaacs, MD)
  • H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

    Contact: Principal Investigator (Hyo Heather Han, MD)
  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Principal Investigator (Heather Han, MD)
  • Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

    Contact: Principal Investigator (Kevin Kalinsky, MD)
  • University of Chicago, Chicago, Illinois, United States

    Study coordinator · 773-834-2756
    Contact: Principal Investigator (Rita Nanda, MD)
  • Loyola University, Maywood, Illinois, United States

    Study coordinator · 708-327-3102
    Contact: Principal Investigator (Kathy S Albain, MD)
  • University of Kansas, Westwood, Kansas, United States

  • Herbert-Herman Cancer Center, Sparrow Hospital, Lansing, Michigan, United States

    Contact: Principal Investigator (Brittani Thomas, DO)
  • University of Minnesota, Minneapolis, Minnesota, United States

    Study coordinator · 612-626-8487
    Contact: Principal Investigator (Douglas Yee, MD)
  • Mayo Clinic, Rochester, Minnesota, United States

    Study coordinator · 507-538-7623
    Contact: Principal Investigator (Judy C Boughey, MD)
  • Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center, Saint Louis Park, Minnesota, United States

    Contact: Principal Investigator (Satya Bommakanti, MD)
  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

    Study coordinator · 732-235-7356
    Contact: Principal Investigator (Coral Omene, MD, PhD)
  • Roswell Park Cancer Institute, Buffalo, New York, United States

    Contact: Principal Investigator (Ellis Levine, MD)
  • Laura and Isaac Perlmutter Cancer Center / NYU Langone Health, New York, New York, United States

    Contact: Study coordinator (Yannis Karamitas) · Yannis.Karamitas@nyulangone.org
    Contact: Principal Investigator (Nancy Chan, MD)
  • Columbia University Medical Center, New York, New York, United States

    Contact: Principal Investigator (Meghana Trivedi, MD)
  • University of Rochester Wilmot Cancer Institute, Rochester, New York, United States

    Contact: Principal Investigator (Carla Folksm, MD)
  • Montefiore Medical Center, The Bronx, New York, United States

    Contact: Principal Investigator (Jesus D Anampa)
  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

    Contact: Study coordinator (Angela Howell, MD) · anhowell@wakehealth.edu · 336-716-5440
    Contact: Principal Investigator (Marissa Howard-McNatt, MD)
  • Cleveland Clinic, Cleveland, Ohio, United States

    Study coordinator · 800-233-2273
    Contact: Principal Investigator (Julie Lang, MD)
  • The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio, United States

    Contact: Principal Investigator (Nicole Williams, MD)
  • Oregon Health & Science Institute (OHSU), Portland, Oregon, United States

    Contact: Study coordinator (Brienna Palm) · palmb@ohsu.edu · 503-494-4438
    Study coordinator · 503-494-8573
    Contact: Principal Investigator (Alexandra Zimmer, MD)
  • University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States

    Study coordinator · 215-614-1850
    Contact: Principal Investigator (Amy Clark, MD)
  • University Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

  • Sanford Clinical Research, Sioux Falls, South Dakota, United States

    Contact: Principal Investigator (Amy Sanford, MD)
  • Vanderbilt University Medical Center, Nashville, Tennessee, United States

  • University of Texas, Southwestern Medical Center, Dallas, Texas, United States

  • University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

    Contact: Principal Investigator (Christos Vaklavas, MD)
  • Inova Health System, Falls Church, Virginia, United States

  • Swedish Cancer Institute, Seattle, Washington, United States

  • University of Washington, Seattle, Washington, United States

מובילי המחקר
  • Laura Esserman, MD, MBA

    Principal Investigator

    University of California, San Francisco